Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001213900-25-042943
Filing Date
2025-05-14
Accepted
2025-05-14 07:05:54
Documents
72
Period of Report
2025-03-31

Document Format Files

Seq Description Document Type Size
1 QUARTERLY REPORT ea0240849-10q_unicycive.htm   iXBRL 10-Q 775249
2 CERTIFICATION ea024084901ex31-1_unicycive.htm EX-31.1 11379
3 CERTIFICATION ea024084901ex31-2_unicycive.htm EX-31.2 11376
4 CERTIFICATION ea024084901ex32-1_unicycive.htm EX-32.1 4181
5 CERTIFICATION ea024084901ex32-2_unicycive.htm EX-32.2 4085
  Complete submission text file 0001213900-25-042943.txt   6074225

Data Files

Seq Description Document Type Size
6 XBRL SCHEMA FILE uncy-20250331.xsd EX-101.SCH 61306
7 XBRL CALCULATION FILE uncy-20250331_cal.xml EX-101.CAL 34097
8 XBRL DEFINITION FILE uncy-20250331_def.xml EX-101.DEF 301421
9 XBRL LABEL FILE uncy-20250331_lab.xml EX-101.LAB 552221
10 XBRL PRESENTATION FILE uncy-20250331_pre.xml EX-101.PRE 323677
74 EXTRACTED XBRL INSTANCE DOCUMENT ea0240849-10q_unicycive_htm.xml XML 707220
Mailing Address 4300 EL CAMINO REAL, SUITE 210 LOS ALTOS CA 94022
Business Address 4300 EL CAMINO REAL, SUITE 210 LOS ALTOS CA 94022 650-384-0642
Unicycive Therapeutics, Inc. (Filer) CIK: 0001766140 (see all company filings)

EIN.: 813638692 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-40582 | Film No.: 25942602
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)